RxDoctor Payments Data

Christopher Diblasio, MD

Urology · Bonita Springs, FLNPI 1952524274

Payments from drug & device makers

$76,019in general payments, 2019–2025

Across 219 payments — averaging $347.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$68K
  • Teleflex LLC$2K
  • Profound Medical Corp.$1K
  • Valencia Technologies Corporation$706
  • Johnson & Johnson$508
  • Dendreon Pharmaceuticals LLC$438
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$62,32882%
  • Travel & lodging$6,8589%
  • Food & beverage$6,7199%
  • Education$1140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,019 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$296,185
Medicare patients
584
Services billed
3,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide15$216,073
OrgovyxRelugolix63$162,190
GemtesaVibegron55$51,271
MyrbetriqMirabegron18$20,200
Methenamine Hippurate93$6,536
Tamsulosin Hcl333$5,985
Finasteride237$3,429
Silodosin27$2,503
Oxybutynin Chloride ErOxybutynin Chloride111$2,303
Dutasteride43$1,967
Alfuzosin Hcl ErAlfuzosin Hcl62$1,701
Potassium Citrate ErPotassium Citrate24$1,698
Cefdinir112$1,574
Testosterone Cypionate23$1,569
Doxycycline Monohydrate83$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$112$236,27333 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$129$213,461118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in Bonita Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →